| Literature DB >> 12669475 |
Abstract
OraSense Ltd (a joint venture between Isis Pharmaceuticals Inc and Elan Corp) is developing ISIS-104838, an antisense oligonucleotide specific for TNF alpha mRNA, as an inhibitor of TNF alpha synthesis. The compound is being developed for the potential treatment of inflammatory diseases such as rheumatoid arthritis, Crohn's disease and psoriasis. This antisense oligonucleotide is currently undergoing phase II clinical trials for RA and Crohn's disease.Entities:
Mesh：
Substances：
Year: 2003 PMID： 12669475
Source DB: PubMed Journal: Curr Opin Mol Ther ISSN： 1464-8431